Meghmani Organics Limited Schedules Board Meeting for April 4, 2026 to Consider Scheme of Amalgamation
Meghmani Organics Limited has scheduled a board meeting for April 4, 2026, to consider and approve a Scheme of Amalgamation. The company notified both NSE and BSE on March 31, 2026, maintaining regulatory compliance. The meeting represents a significant corporate restructuring initiative requiring board-level approval and proper governance protocols.

*this image is generated using AI for illustrative purposes only.
Meghmani Organics Limited has announced a board meeting scheduled for April 4, 2026, to consider and approve a Scheme of Amalgamation. The company formally notified both major stock exchanges about this important corporate development on March 31, 2026.
Board Meeting Details
The meeting of the Board of Directors is scheduled for Saturday, April 4, 2026, with the primary agenda focusing on the consideration, review, and approval of a Scheme of Amalgamation. This represents a significant corporate restructuring initiative that requires board-level approval and regulatory compliance.
| Meeting Parameter: | Details |
|---|---|
| Meeting Date: | Saturday, April 4, 2026 |
| Primary Agenda: | Scheme of Amalgamation |
| Notification Date: | March 31, 2026 |
| Reference Number: | MOL/2025-26/75 |
Regulatory Compliance
The company has fulfilled its disclosure obligations by informing both the National Stock Exchange of India Limited and BSE Limited about the upcoming board meeting. The notification was signed by Jayesh Patel, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols are followed.
Exchange Communication
Meghmani Organics Limited communicated the board meeting details to both stock exchanges where its shares are listed. The company trades on NSE under the symbol MOL and on BSE with scrip code 543331. The formal notification ensures transparency and keeps all stakeholders informed about this significant corporate action.
The Scheme of Amalgamation represents a strategic corporate restructuring move that will require thorough board deliberation and subsequent regulatory approvals. The company has maintained proper disclosure standards by providing advance notice to the exchanges and market participants.
Which specific companies or subsidiaries are likely to be involved in Meghmani Organics' amalgamation scheme?
How might this amalgamation impact Meghmani Organics' market position in the specialty chemicals and agrochemicals sector?
What timeline can shareholders expect for regulatory approvals and completion of the amalgamation process?

































